Minimed Group

What Minimed Group does

MiniMed Group is a global diabetes management company that develops, manufactures, and markets integrated diabetes therapy solutions for insulin-dependent patients. Spun off from Medtronic and IPO'd on Nasdaq in March 2026 under ticker MMED, the company serves over 640,000 insulin pump users across approximately 80 countries through a portfolio spanning insulin pumps (MiniMed Flex, MiniMed 780G), continuous glucose monitoring sensors (Simplera Sync, Guardian 4, Abbott Instinct), smart insulin pens (InPen), and cloud-based therapy management software (CareLink Personal). The company's core technology platform is SmartGuard, an automated insulin delivery algorithm that adjusts basal insulin every 5 minutes based on real-time CGM readings and can suspend delivery when glucose falls below predefined thresholds; algorithm development includes contributions from DreaMed Diabetes.

The business model is anchored to a recurring consumables revenue stream, with approximately 83% of FY25 revenue ($2.7-2.9 billion) generated from CGM sensors, infusion sets, reservoirs, software, and services tied to the installed pump base. Hardware sales (pumps) represent the smaller balance. Distribution combines direct-to-consumer channels (minimed.com, diabetes.shop, 1-800-MINIMED) that handle insurance verification and prescription confirmation with a separate healthcare professional portal for clinical prescribing. The company achieved 57% gross margins in FY25 but remains unprofitable with a $145 million operating loss as it invests in growth and absorbs spin-off costs.

Following its March 2026 IPO, Medtronic retained approximately 80.1% voting power with plans for an eventual tax-free spin-off distribution to shareholders. Strategic priorities include scaling the newly FDA-cleared MiniMed Flex screenless pump, commercializing the 780G with Abbott's Instinct CGM sensor across European markets in summer 2026, and leveraging the $560 million IPO proceeds to fund independent R&D and commercial expansion.

Name

Minimed Group

Legal name

Medtronic MiniMed, Inc.

Website

https://minimed.com

Company type

Public

Founded year

2026

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

MiniMed Group is a diabetes management company that develops insulin pumps, CGM sensors, smart insulin pens, and therapy software for insulin-dependent patients. Spun off from Medtronic in March 2026, it serves 640,000+ pump users across 80 countries with ~83% of revenue from recurring consumables.

Ownership category

akta.pro rank

Product category

Diabetes Management Devices

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro industry

PRIMARYHLAHAIAG

Insulin Pumps & Patch Pumps

Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

SECONDARYHLAHAHAF

Automated Insulin Delivery (AID) / Closed-Loop Systems

Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

SECONDARYHLAHAHAC

Patch Pumps & Wearable Insulin Delivery

Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

SECONDARYHLAHAHAJ

Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

• Insulin pump systems
• Continuous glucose monitoring
• Automated insulin delivery
• Diabetes management devices
• Smart insulin pen

Headquarters

HQ city

Northridge

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Insulin Pump Hardware: Sale of insulin pump devices including MiniMed Flex, MiniMed 780G, and related systems. Revenue is one-time per device with typical replacement cycles.
2. Consumables (Sensors, Infusion Sets, Reservoirs): Approximately 83% of revenue comes from consumables including CGM sensors (Simplera Sync, Guardian 4, Instinct), infusion sets, and reservoirs. Sensors typically have 6-15 day wear periods requiring regular replacement.
3. Software and Services: CareLink Personal therapy management software, mobile apps, and related digital services. Part of the recurring revenue stream from the installed base of pump users.
4. Insurance and Billing Services: The company handles insurance verification, billing, and paperwork for patients as part of its customer service offering, supporting the hardware and consumables revenue streams.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

MiniMed Group designs, manufactures, and sells integrated diabetes management systems including automated insulin delivery pumps (MiniMed Flex, MiniMed 780G), multiple daily injection therapy systems (MiniMed Go with InPen smart insulin pen), continuous glucose monitoring (CGM) sensors (Simplera Sync, Guardian 4), and cloud-based therapy management software (CareLink Personal). The company's SmartGuard technology automates insulin adjustment every 5 minutes based on CGM readings and can suspend delivery when glucose falls below predefined thresholds. Approximately 83% of revenue comes from recurring consumables (sensors, infusion sets, reservoirs), software, and services tied to its installed base of 640,000+ pump users across 80 countries.

Product overview

MiniMed Group is a global diabetes management company that develops, manufactures, and markets integrated diabetes therapy solutions. The company offers a portfolio of FDA-cleared medical devices including insulin pumps (MiniMed Flex, MiniMed 780G), smart insulin pens (InPen), continuous glucose monitoring sensors (Simplera Sync, Guardian 4, Guardian 3, Abbott Instinct), and therapy management software (CareLink Personal). The MiniMed 780G system with SmartGuard technology represents the core advanced automated insulin delivery platform, while MiniMed Go extends the portfolio to multiple daily injection users. The company operates in approximately 80 countries and serves over 640,000 insulin pump users globally.

Differentiator

Problem solved

Functional benefit

Brands

• MiniMed Flex: Screenless insulin pump automation system, approximately half the size of previous models, FDA-cleared for type 1 and type 2 diabetes management.
• MiniMed 780G
• MiniMed Go
• InPen
• Guardian Sensor 4
• CareLink Personal
• MiniMed Mobile App

Products and services

• MiniMed Flex System Screenless, smartphone-controlled insulin pump system with SmartGuard technology for automated basal insulin adjustment and delivery suspension. Approximately half the size of the MiniMed 780G and compatible with the Simplera Sync disposable CGM sensor. Designed for continuous subcutaneous insulin infusion (CSII) therapy in people with Type 1 or insulin-requiring Type 2 diabetes.
• MiniMed 780G System Advanced automated insulin delivery system with SmartGuard technology that automatically corrects sugar levels every 5 minutes based on real-time CGM readings to optimize Time in Range. Compatible with Instinct, Simplera Sync, and Guardian 4 sensors. Indicated for Type 1 diabetes in persons aged 7+ and Type 2 diabetes in persons aged 18+ requiring insulin.
• MiniMed Go System Multiple daily injection (MDI) therapy management system that combines the InPen smart insulin pen with CGM integration (Instinct or Simplera) and the MiniMed mobile app to provide real-time dosing guidance, dose tracking, and glucose monitoring for patients who manage diabetes with daily injections.
• InPen Smart Insulin Pen Bluetooth-enabled reusable smart insulin pen that administers rapid-acting insulin (Humalog, Novolog, Fiasp) and tracks doses via the companion MiniMed app. The app displays the last dose, calculates next dose timing, and sends reminders. Used as a standalone or as part of the MiniMed Go system for MDI therapy.
• CareLink Personal Software Cloud-based therapy management software platform that aggregates data from MiniMed insulin pumps and CGM sensors. Enables users to view therapy data, generate reports, share information with healthcare providers, and supports remote monitoring and clinical decision-making for diabetes management.
• MiniMed Infusion Sets Disposable infusion sets that connect MiniMed insulin pumps to the body for continuous insulin delivery, including standard sets and the Medtronic Extended infusion set with longer wear capability up to 7 days.
• MiniMed Reservoirs Disposable insulin reservoirs for MiniMed insulin pumps that hold and deliver insulin through the pump system as part of routine pump therapy.
• i-Port Advance Injection Port Injection port device that allows multiple insulin injections through a single skin site, reducing the number of skin punctures required for patients managing diabetes with multiple daily injections.

Quantifiable outcome

• Time in Range improvement through automated insulin correction every 5 minutes
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration10 records

AI capability4 records

Feature7 records

Partnerships

Two partnerships are on record, tiered core.

• AbbottcoreTechnology or Integration · 10 March 2026MiniMed received CE Mark approval for its MiniMed 780G automated insulin delivery system to be used with Abbott's Instinct continuous glucose monitoring sensor in Europe. The Instinct sensor is the world's smallest and thinnest CGM, offering up to 15 days of wear compared to 7-day options already compatible with the system. Commercial launch in first European countries expected summer 2026.
• DreaMed DiabetescoreTechnology or IntegrationDreaMed Diabetes is a trademark of DreaMed Diabetes, Ltd. The MiniMed 780G system algorithm includes technology developed by DreaMed Diabetes for automated insulin delivery optimization.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• Ypsomed: Swiss-based Ypsomed manufactures the mylife YpsoPump and is building an AID ecosystem with CamDiab and Dexcom, positioning itself as a focused European competitor to MiniMed in the tubed and patch pump category.
• Bigfoot Biomedical: Bigfoot Unity was a smart insulin pen + CGM integrated system for Type 2 diabetes, comparable to MiniMed Go, though Bigfoot has shifted focus and reduced commercial operations — representative of the niche smart-pen-AID category MiniMed competes in.
• Embecta: Embecta (spun off from BD in 2022) is a pure-play diabetes injection device company whose insulin patch pen and pen needles compete directly with MiniMed's InPen smart pen and infusion set consumables in the MDI segment.

Regional players

• LifeScan: LifeScan (Platinum Equity-owned) markets the OneTouch blood glucose monitoring portfolio with consumer-oriented diabetes management, primarily outside the integrated pump-AID category but a peripheral competitor for patient mindshare and diabetes management tools.

Broad incumbents

• Roche Diabetes Care: Roche's Accu-Chek SmartGuide and Accu-Chek Insight pump system compete broadly with MiniMed across integrated diabetes management, particularly in European markets where Roche has deep pharmacy and reimbursement relationships.
• Dexcom: Dexcom is the leading standalone CGM manufacturer (G6/G7) whose sensors are integrated with Tandem and Insulet pumps but historically less central to MiniMed's ecosystem, making it both a competitor for sensor revenue and a complementary component for MiniMed's installed base.
• Abbott Diabetes Care: Abbott's FreeStyle Libre is the dominant consumer CGM globally, and Abbott is also MiniMed's CGM partner through the new Instinct sensor exclusive to MiniMed 780G in Europe — making Abbott simultaneously a supplier, partner, and broad-market competitor in the integrated diabetes management space.
• Medtronic plc: Medtronic remains MiniMed's ~80.1% controlling shareholder and operates other diabetes-adjacent businesses (Continuous Glucose Monitoring legacy business divested, but Medtronic retains certain non-compete and supply obligations) that overlap with MiniMed's portfolio.

Direct peers

• Tandem Diabetes Care: Tandem manufactures the t:slim X2 insulin pump with Control-IQ automated insulin delivery algorithm integrated with Dexcom CGM, directly competing with MiniMed 780G for Type 1 diabetes pump starts and replacements in the U.S. and select international markets.
• Insulet Corporation: Insulet's Omnipod 5 tubeless patch pump is the closest direct competitor to MiniMed in automated insulin delivery, integrated with Dexcom G6/G7 and Abbott FreeStyle Libre CGMs, and has been gaining share among both pediatric and adult Type 1 patients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/minimed
• YouTubeyoutube.com/@minimed_US
• Facebookfacebook.com/minimed
• LinkedInlinkedin.com/company/minimed-diabetes
• Instagraminstagram.com/minimed
• TikToktiktok.com/@minimed

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Minimed Group